The Latest

Trokendi-XR

Supernus Pharmaceuticals has launched a new “Emoji” style campaign for Trokendi XR to display how migraine patients receiving 100 mg/day or less of topiramate aren’t experiencing its full potential. This campaign encouraged physicians to try for more migraine prevention by converting their immediate-release topiramate patients to once-daily Trokendi XR.

Additional examples of promotional campaigns are available with a subscription to CD Promo WorldWide. Contact Christine Alongi at alongi@dtwresearch.com for more information.

NOW AVAILABLE: For the Immunoglobulin Market – A SnapShot analysis of HCP targeted promotional messaging and DTC initiatives for Q2 2017.

Overall, 16 new pieces were received for the Immunoglobulin therapy market during the second quarter, showing a 45% increase in promotional volume from Quarter 1. The leader of promotional distribution shifted from Grifols’s Gamunex-C to CSL Behring’s Hizentra during this quarter. Shire’s DTC campaign for Cuvitru continued to inspire patients to take control of their treatment and fight back against PI. CSL Behring promoted its two Ig products, Hizentra and Privigen, as the leading Ig therapies. Additional insights into marketing strategies and channel utilization across all PI brands are available in the full Q2 report.

Q2-2017-Immuno

About SnapShot

Helping to keep you abreast of key competitor’s marketing strategies, CD Promo SnapShot is a quarterly competitive intelligence service of dtw Research, Inc. Snapshot reports provide an analytical view into the messaging and marketing tactics within specific therapeutic areas. The reports are sourced from dtw’s CD Promo WorldWide, our online  database of virtually all digital and print promotion distributed by the pharmaceutical industry since 1996. SnapShot reports include a detailed analysis of each brand’s messaging evolution, physician and DTC campaign initiatives, efficacy/comparative data, dosing, patient access, education and support programs, and more. Reports are available by annual subscription for over 50 primary and specialty markets.

For more information please contact:

US Markets: Christine Alongi at Alongi@dtwresearch.com  \\ Ex-US Markets: Robin Cefalo at Cefalo@dtwresearch.com

Tagged with:
 

NOW AVAILABLE: For the Immune Thrombocytopenic Purpura (ITP) Market – A SnapShot analysis of HCP targeted promotional messaging and DTC initiatives for Q2 2017

Overall, 16 new pieces were received across the brands observed within the ITP market, presenting a 45% increase from Q1. This increase featured the addition of Rigel Pharmaceuticals’ Tavalisse, which included press releases announcing its proprietary name and New Drug Application status. Novartis’s Promacta continued to hold the largest share of promotional volume between all brands, acquiring 69% in total. Within Promacta’s analysis, a new visual campaign featured a woman walking across a bridge of platelets to symbolize long-term response. Additional insights into marketing strategies and channel utilization are available in the full Q2 report.

Q2-2017-ITP

About SnapShot

Helping to keep you abreast of key competitor’s marketing strategies, CD Promo SnapShot is a quarterly competitive intelligence service of dtw Research, Inc. Snapshot reports provide an analytical view into the messaging and marketing tactics within specific therapeutic areas. The reports are sourced from dtw’s CD Promo WorldWide, our online  database of virtually all digital and print promotion distributed by the pharmaceutical industry since 1996. SnapShot reports include a detailed analysis of each brand’s messaging evolution, physician and DTC campaign initiatives, efficacy/comparative data, dosing, patient access, education and support programs, and more.

Reports are available by annual subscription for over 50 primary and specialty markets.

For more information please contact: US Markets: Christine Alongi at Alongi@dtwresearch.com  \\ Ex-US Markets: Robin Cefalo at Cefalo@dtwresearch.com

 NOW AVAILABLE: For the Vaccines Market – A SnapShot analysis of HCP targeted promotional messaging and DTC initiatives for Q2 2017.

When taking a look at distributional volume between five corporations in the vaccines market, the majority of marketing materials were received for Merck, comprising 27% of the 51 new pieces received. Of the 51 new pieces received, 29% were indicated for pneumonia. Highlights for each indication are as follows:

  • HPV: Merck’s Gardasil 9 presented the “One Less” DTC campaign, which highlighted HPV-related cancer prevention.
  • Flu: Sanofi distributed the most pieces, which highlighted Fluzone High-Dose’s familiar “Defense” campaign and support with the Fluzone Partners Program.
  • Meningitis: GlaxoSmithKline produced the most pieces and featured the new Bexsero “Fast” campaign, which emphasized Bexsero’s fast series completion.
  • Pediatric vaccines: Sanofi provided a guide to implementing a Pentacel and Quadracel vaccine schedule.
  • Pneumonia: Merck’s Pneumovax 23 and Pfizer’s Prevnar 13 produced an equal number of pieces this quarter.
  • Shingles: Merck’s Zostavax encouraged patients and healthcare professionals to vaccinate with Zostavax.

Additional insights into marketing strategies and channel utilization are available in the full Q2 report.Q2-2017-Vaccine-CorpQ2-2017-Vaccine-Indications

About SnapShot

Helping to keep you abreast of key competitor’s marketing strategies, CD Promo SnapShot is a quarterly competitive intelligence service of dtw Research, Inc. Snapshot reports provide an analytical view into the messaging and marketing tactics within specific therapeutic areas. The reports are sourced from dtw’s CD Promo WorldWide, our online database of virtually all digital and print promotion distributed by the pharmaceutical industry since 1996. SnapShot reports include a detailed analysis of each brand’s messaging evolution, physician and DTC campaign initiatives, efficacy/comparative data, dosing, patient access, education and support programs, and more.

Reports are available by annual subscription for over 50 primary and specialty markets.

For more information please contact:

US Markets: Christine Alongi at Alongi@dtwresearch.com

Ex-US Markets: Robin Cefalo at Cefalo@dtwresearch.com

NOW AVAILABLE: For the Diabetes Insulin Market – A SnapShot analysis of HCP targeted promotional messaging and DTC initiatives for Q2 2017.

Within the SnapShot markets, diabetes insulin is observed as one of the leading therapy areas in terms of marketing material outreach with an average production of over 150 new pieces circulated per quarter. When taking a look at distributional volume between all brands in Q2, the majority of marketing materials were received for Sanofi’s Toujeo, which comprised 21% of the promotional volume received. A number of promotions from Sanofi advertised Lantus and Toujeo formulary coverage and cost savings with the Sanofi Rx Savings Program. Sanofi’s Soliqua presented the new “Percentage” campaign, which emphasized patients putting high HbA1c percentages behind them. Novo Nordisk’s Xultophy provided patients with treatment information and healthcare professionals with steps to starting their patients on Xultophy. Admelog entered the market with a prelaunch medical education piece from Sanofi. Additional insights into marketing strategies and channel utilization are available in the full Q2 report.

Q2-2017-Diabetes-Insulin

About SnapShot

Helping to keep you abreast of key competitor’s marketing strategies, CD Promo SnapShot is a quarterly competitive intelligence service of dtw Research, Inc. Snapshot reports provide an analytical view into the messaging and marketing tactics within specific therapeutic areas. The reports are sourced from dtw’s CD Promo WorldWide, our online database of virtually all digital and print promotion distributed by the pharmaceutical industry since 1996. SnapShot reports include a detailed analysis of each brand’s messaging evolution, physician and DTC campaign initiatives, efficacy/comparative data, dosing, patient access, education and support programs, and more.

Reports are available by annual subscription for over 50 primary and specialty markets.

For more information please contact:

US Markets: Christine Alongi at Alongi@dtwresearch.com

Ex-US Markets: Robin Cefalo at Cefalo@dtwresearch.com

Tagged with:
 

NOW AVAILABLE: For the U.S. Antipsychotic Market – A SnapShot analysis of HCP targeted promotional messaging and DTC initiatives for Q2 2017.

A total of 78 new pieces were received for ten brands within the antipsychotic market during this time period. Otsuka’s Abilify Maintena campaign was the most robust of all products analyzed, with 25% of the promotional content for the therapeutic class. Abilify Maintena launched a new consumer campaign, which highlights patients who have been set back by schizophrenia, but are determined to live the life they were born to lead. Alkermes announced a new dosing option for Aristada, making it “the first and only LAI for schizophrenia to offer a 2-month dosing interval.” Janssen encouraged physicians to implement the STEP (Sequential Therapeutic Engagement Plan) dosing plan for Invega Sustenna and Invega Trinza. Allergan integrated another “celebration” into the Vraylar campaign, noting the products one year anniversary since FDA approval, along with key milestones. Additional insights into marketing strategies and channel utilization are available in the full Q2 report.

Q2-2017-Antipsych

About SnapShot

Helping to keep you abreast of key competitor’s marketing strategies, CD Promo SnapShot is a quarterly competitive intelligence service of dtw Research, Inc. Snapshot reports provide an analytical view into the messaging and marketing tactics within specific therapeutic areas. The reports are sourced from dtw’s CD Promo WorldWide, our online database of virtually all digital and print promotion distributed by the pharmaceutical industry since 1996. SnapShot reports include a detailed analysis of each brand’s messaging evolution, physician and DTC campaign initiatives, efficacy/comparative data, dosing, patient access, education and support programs, and more.

Reports are available by annual subscription for over 50 primary and specialty markets.

For more information please contact: US Markets: Christine Alongi at Alongi@dtwresearch.com \\  Ex-US Markets: Robin Cefalo at Cefalo@dtwresearch.com

NOW AVAILABLE: For the Leukemia Market – A SnapShot analysis of HCP targeted promotional messaging and DTC initiatives for Q2 2017.

Of the six brands actively circulating promotions during the second quarter of 2017, Janssen’s Imbruvica remained the leukemia market leader in terms of promotional volume with 12 new pieces. Imbruvica noted an increase in the number of patients treated and its impressive FDA approval timeline. Genentech BioOncology announced that Rituxan Hycela is now approved for FL, DLBCL, and CLL. Teva Oncology continued to emphasize Bendeka’s fixed course of therapy with the relatively new “Time Off” campaign. AbbVie/Genentech’s Venclexta and Novartis’s Arzerra utilized digital channels to communicate key messaging. Additional insights into marketing strategies and channel utilization are available in the full Q2 report.

Q2-2017-Leukemia-

About SnapShot

Helping to keep you abreast of key competitor’s marketing strategies, CD Promo SnapShot is a quarterly competitive intelligence service of dtw Research, Inc. Snapshot reports provide an analytical view into the messaging and marketing tactics within specific therapeutic areas. The reports are sourced from dtw’s CD Promo WorldWide, our online database of virtually all digital and print promotion distributed by the pharmaceutical industry since 1996. SnapShot reports include a detailed analysis of each brand’s messaging evolution, physician and DTC campaign initiatives, efficacy/comparative data, dosing, patient access, education and support programs, and more.

Reports are available by annual subscription for over 50 primary and specialty markets.

For more information please contact:

US Markets: Christine Alongi at Alongi@dtwresearch.com

Ex-US Markets: Robin Cefalo at Cefalo@dtwresearch.com

NOW AVAILABLE: For the U.S. Lymphoma Market – A SnapShot analysis of HCP targeted promotional messaging and DTC initiatives for Q2 2017.

Compared to the previous quarter, market volume increased by 33%, with Imbruvica from Janssen and Pharmacyclics maintaining its status as leader in terms of the proportion of promotional materials received. Kite Pharma entered the promotional arena with its first unbranded piece encouraging healthcare professionals to learn more about CAR T technology. Introductory promotions were also noted for Rituxan Hycela as Genentech and Biogen announced the product’s approval alongside the “New Chapter” launch theme. Additional campaign imagery included Celgene’s unbranded “Distant Memory” theme, Gilead’s “B-Cell” imagery for Zydelig, and Bendeka’s relatively new “Time Off” campaign from Teva. In addition, Imbruvica continued the “Boot Print” theme as it emphasized its experience and versatility with a timeline of its approvals for seven indications over four years, including the most recent for MZL. Support and education remained the most widespread topics discussed, along with clinical trial data in support of efficacy. A complete visualization of these campaigns, as well as additional insights pertaining to the marketing strategies and channel utilization of brands competing within this market, are available to CD Promo SnapShot Subscribers, via the Q2 2017 report.

Q2-2017-Lymphoma-Images

About SnapShot

Helping to keep you abreast of key competitor’s marketing strategies, CD Promo SnapShot is a quarterly competitive intelligence service of dtw Research, Inc. Snapshot reports provide an analytical view into the messaging and marketing tactics within specific therapeutic areas. The reports are sourced from dtw’s CD Promo WorldWide, our online database of virtually all digital and print promotion distributed by the pharmaceutical industry since 1996. SnapShot reports include a detailed analysis of each brand’s messaging evolution, physician and DTC campaign initiatives, efficacy/comparative data, dosing, patient access, education and support programs, and more.

Reports are available by annual subscription for over 50 primary and specialty markets.

For more information please contact:

US Markets: Christine Alongi at Alongi@dtwresearch.com

Ex-US Markets: Robin Cefalo at Cefalo@dtwresearch.com

Tagged with:
 

NOW AVAILABLE: For the U.S. Antimigraine Market – A SnapShot analysis of HCP targeted promotional messaging and DTC initiatives for Q2 2017.

Market volume increased by 28% over the previous quarter, with Trokendi XR from Supernus Pharmaceuticals as the decisive leader, greatly expanding its marketing to produce 36% of the materials received in support of its new indication for migraine prevention. Upsher-Smith’s Qudexy XR also made a strong showing as it promoted its approval for prophylaxis along with the introduction of the Access Pathways support program. Multiple campaign themes were noted, with new imagery seen from Trokendi XR and a variation on a more familiar theme by Allergan for Botox. Unbranded “Science of Migraine” materials were distributed by Amgen and Novartis as they worked toward approval of erenumab. The majority of brands continued to place heavy emphasis on messaging regarding education, support, and savings, although efficacy was consistently highlighted as well. A complete visualization of these campaigns, as well as additional insights pertaining to the marketing strategies and channel utilization of brands competing within this market, are available to CD Promo SnapShot Subscribers, via the Q2 2017 report.

 

Q2-2017-Antimigraine

About SnapShot

Helping to keep you abreast of key competitor’s marketing strategies, CD Promo SnapShot is a quarterly competitive intelligence service of dtw Research, Inc. Snapshot reports provide an analytical view into the messaging and marketing tactics within specific therapeutic areas. The reports are sourced from dtw’s CD Promo WorldWide, our online database of virtually all digital and print promotion distributed by the pharmaceutical industry since 1996. SnapShot reports include a detailed analysis of each brand’s messaging evolution, physician and DTC campaign initiatives, efficacy/comparative data, dosing, patient access, education and support programs, and more.

Reports are available by annual subscription for over 50 primary and specialty markets.

For more information please contact:

US Markets: Christine Alongi at Alongi@dtwresearch.com

Ex-US Markets: Robin Cefalo at Cefalo@dtwresearch.com

NOW AVAILABLE: For the European Spondyloarthropathies (AS & nr-axSpA) Market – A SnapShot analysis of promotional messaging and DTC initiatives for Q2, 2017.

The Spondyloarthropathies market for AS and nr-axSpA generated 99 pieces in Q2, with Humira capturing almost a quarter of the overall promotional volume (24%). Janssen’s Simponi announced its approval for the treatment of nr-axSpA. Patient support and convenience were the main focus for UCB’s Cimzia (AutoClicks pen), Pfizer’s Enbrel (MYCLIC pen), and AbbVie’s Humira (40mg/0.4 mL enhanced presentation). In addition, patient support through Enbrel’s TOGETHER program, “My Humira” injection program, and Remicade’s AMI patient service were emphasized. Clinical studies in real practice, and cost-savings agreements were also the promotional highlights during this quarter. Additional insights into marketing strategies and channel utilization are available in the full Q2 report.

AS-Q2-2017

About SnapShot

Helping to keep abreast of key competitor’s marketing strategies, CD Promo SnapShot is a quarterly competitive intelligence service of dtw Research, Inc. Snapshot reports provide an analytical view into the messaging and marketing tactics within specific therapeutic areas. The reports are sourced from dtw’s CD Promo WorldWide, the digitalized database of virtually all promotional materials distributed by the pharmaceutical industry since 1996. SnapShot reports include a detailed analysis of each brand’s messaging evolution, physician and DTC campaign initiatives, efficacy/comparative data, dosing, patient access, education and support programs, and more.

Reports are available by annual subscription for over 50 primary and specialty markets.
For more information please contact:

US Markets: Christine Alongi at Alongi@dtwresearch.com

Ex-US Markets: Robin Cefalo at Cefalo@dtwresearch.com

Tagged with: